


CABOMETYX™
(cabozantinib) tablets

OVERVIEW

CLINICAL INFORMATION

DRUG MONOGRAPH



CABOMETYX™
(cabozantinib) tablets
60 mg | 40 mg | 20 mg

CABOMETYX™ is now approved in patients who have received prior therapy* for advanced renal cell carcinoma (RCC)¹


*Anti-angiogenic therapy.

**NCCN Clinical Practice Guidelines in Oncology
(NCCN Guidelines®) Category 1 Recommendation²**

Cabozantinib (CABOMETYX™) has a Category 1 recommendation for patients with advanced clear cell histology RCC after prior anti-angiogenic therapy.

CABOMETYX™ is the only single agent to demonstrate significant improvement across 3 endpoints—overall survival (OS), progression-free survival (PFS), and objective response rate (ORR)—in advanced RCC after prior treatment^{1*}

*Anti-angiogenic therapy.



Based on the results of the METEOR trial,¹ the NCCN Guidelines® include cabozantinib (CABOMETYX™) as a Category 1 subsequent therapy option in patients with advanced clear cell RCC who have been previously treated with anti-angiogenic therapy, and note that eligible patients should preferentially receive it over everolimus.²



QUICK START PROGRAM

Eligible patients receive a 15-day supply at no cost

- Available for new patients who experience a delay of more than 5 days in the processing or approval of their prescription for CABOMETYX™

MPR MONOGRAPH R



CABOMETYX™
(cabozantinib) tablets

COMPANY:

Exelixis®

PHARMACOLOGIC CLASS:

Receptor tyrosine kinase inhibitor

Would you like additional information?

[Download Alert](#)

Enter your email

Submit

Additional Links:

[Visit CABOMETYX™ Website](#)[Download Dosing and Administration Guide](#)[Download Patient Q&A](#)[Access EASE Enrollment Form](#)

CABOMETYX™ (cabozantinib) tablets



OVERVIEW



CLINICAL INFORMATION



DRUG MONOGRAPH

**CABOMETYX™ is now
approved in patients who
have received prior
therapy* for advanced
renal cell carcinoma
(RCC)¹**

*Anti-angiogenic therapy.

**NCCN Clinical Practice Guidelines
in Oncology (NCCN Guidelines®)**

CABOMETYX™

(cabozantinib) tablets



CABOMETYX™

(cabozantinib) tablets

60 mg | 40 mg | 20 mg

CABOMETYX™ is now approved in patients who have received prior therapy* for advanced renal cell carcinoma (RCC)¹


*Anti-angiogenic therapy.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Category 1 Recommendation²

Cabozantinib (CABOMETYX™) has a Category 1 recommendation for patients with advanced clear cell histology RCC after prior treatment with anti-angiogenic therapy.

CABOMETYX™ is the only single agent to demonstrate significant improvement across 3 endpoints—overall survival (OS), progression-free survival (PFS), and objective response rate (ORR)—in advanced RCC after prior treatment^{1*}

*Anti-angiogenic therapy.



Based on the results of the METEOR trial,¹ the NCCN Guidelines® include cabozantinib (CABOMETYX™) as a Category 1 subsequent therapy option in patients with advanced clear cell RCC who have been previously treated with anti-angiogenic therapy, and note that eligible patients should preferentially receive it over everolimus.²

QUICK START PROGRAM

Eligible patients receive a 15-day supply at no cost

- Available for new patients who experience a delay of more than 5 days in the processing or approval of their prescription for CABOMETYX™

Enter your email

Submit



[Download Alert](#)

Would you like additional information?

- Additional Links:
 - Visit CABOMETYX™ Website
 - Download Dosing and Administration Guide
 - Download Patient Q&A
 - Access EASE Enrollment Form